AVAILABILITY OF SURPASS POST-PROJECT

Cineca have been the IT provider of the SurPass since it was first developed in the ENCCA project in 2011-2017. In the final year of the PanCareSurPass project, Cineca made an overall strategic decision to leave the health sector and therefore as well to no longer support the SurPass platform. Intellectual property (IP) related to the SurPass was transferred to IGG, a key partner in the SurPass development in Italy and in the EU-funded research projects. As a hospital, IGG does not have the IT capacity to maintain and provide continued access to the SurPass, which it has become a strategic tool within Italy for delivering Survivorship Care, supported by EU-funded projects, as well as funding from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). IGG sought a new IT company to take over operation of the SurPass, in Italy in the first instance but also in other European countries in the future, as well as to support future development of new functionalities within the SurPass. DataRiver was selected by IGG and a license agreement is now in place between IGG and DataRiver, which allows use of SurPass-related IP by DataRiver. SurPass was certified as a medical device (MD) during PanCareSurPass, and this transfer to a new IT company requires re-certification. SurPass v2.0 cannot be made available to clinics for use in routine care until the re-certification is complete or until Ethics Committee new approval. IGG and DataRiver are now finalising the terms of the MD re-certification and it will be commenced within 2025. This on-going work means that the Implementation Toolkit cannot yet offer interested organisations a clear pathway to implementation of the SurPass. Once the MD re-certification is complete, the expected process would be for interested clinics (including those who participated in PanCareSurPass) to contact IGG and DataRiver to negotiate commercial agreements for access to the SurPass (if already available in the desired language) or for development and access to the SurPass (if a new language is required). This information will be added to the Toolkit as soon as the MD re-certification has been completed.

Disclaimer

PanCare strives to provide accurate and complete information that is up-to-date as of the date of publication.

No warranty or representation, expressed or implied, is made concerning the accuracy, reliability, completeness, relevance, or timeliness of this information.

The PanCare materials are free to use for anyone aiming to inform about late effects and long-term survivorship care. However, no financial advantage may be achieved. All communication should reference PanCare and link to the PanCare website.

PanCareSurPass has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899999. The material presented and views expressed here are the responsibilities of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.